Advertisement
AZTA vs XRAY
Which Stock Would AI Choose? Azenta, Inc. (AZTA) vs. DENTSPLY SIRONA Inc. (XRAY) Stock Comparison
Key Takeaways
- Both AZTA and XRAY operate in the healthcare sector, specifically medical instruments and supplies, but AZTA focuses on life sciences tools while XRAY specializes in dental products.
- AZTA shows stronger YTD performance at approximately 44% gain versus XRAY's flat 0.5% return, amid recent earnings volatility for both.
- XRAY trades at a lower forward P/E (around 8) compared to AZTA's 29, suggesting potentially better value, but carries higher debt via enterprise value.
- Analyst targets indicate upside potential: 35.40 for AZTA (from ~19) and 14.10 for XRAY (from ~11), reflecting relative positioning.
- Recent market activity highlights AZTA's higher beta (1.43) for volatility versus XRAY's steadier 0.94.
Introduction
This stock comparison examines AZTA and XRAY, two healthcare firms in medical instruments and supplies. Investors tracking sector relative performance may find value in contrasting their business models, recent momentum, and market positioning. Traders focused on short-term catalysts like earnings reactions, while long-term holders assess growth drivers in life sciences and dental care amid evolving healthcare demands. With both stocks navigating volatility in recent market activity, this analysis highlights key contrasts for informed decision-making in the current environment.
AZTA Overview and Recent Performance
Azenta, Inc. (AZTA) provides precision solutions for the life sciences industry, including sample management, storage, and automation tools essential for biotech and pharmaceutical research. In recent weeks, AZTA reported second-quarter fiscal 2026 results, with revenue at $144.8 million but an EPS miss of -0.04 against expectations of +0.14, prompting updated full-year guidance. The stock, trading around $19 with a 52-week range of 17.47-41.73, has delivered robust YTD gains near 44%, outperforming broader indices, though longer-term returns lag. Sentiment reflects analyst adjustments, such as Evercore ISI lowering its target to $35 while maintaining Outperform, amid operational challenges and leadership shifts in gene synthesis strategy. Higher beta (1.43) underscores volatility tied to life sciences demand fluctuations.
XRAY Overview and Recent Performance
DENTSPLY SIRONA Inc. (XRAY) is a leading manufacturer of dental products, equipment, and technologies, including consumables and cloud-enabled solutions for oral health professionals. Recent market activity saw XRAY report first-quarter 2026 results, with revenue of $880 million slightly missing estimates but EPS meeting normalized expectations at +0.27. Trading near $11 in a 52-week range of 9.85-17.18, the stock remains roughly flat YTD at 0.5%, underperforming the S&P 500. Developments include expanded U.S. distribution and launch of AI-enabled diagnostic tool Smart View Detect. Analyst targets average $14.10, with recent holds from Argus, as stabilizing sentiment counters longer-term weakness. Lower beta (0.94) indicates relative stability versus peers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies, timeframes, and sectors. Only the most suitable for prevailing market conditions—based on metrics like annualized returns up to 169%, win rates of 51-88%, and profit factors reaching 11.7—earn a spot among the 25 featured out of 351 total bots. These include signal agents for semiconductors, industrials, leveraged ETFs, and more, with performance like 70-80% win rates and low drawdowns. Each bot employs unique styles, from momentum to sector rotation, enabling copy trading with real-time signals. Explore these high-conviction options to align with current trends.
Head-to-Head Comparison
AZTA and XRAY share healthcare sector exposure but diverge in focus: AZTA's life sciences automation targets biotech growth, while XRAY's dental consumables offer defensive stability. Growth drivers contrast with AZTA's innovation in multiomics versus XRAY's AI diagnostics and partnerships. Recent momentum favors AZTA's YTD surge, but XRAY shows valuation edge (forward P/E 7.83 vs. 29.07; P/S 0.61 vs. 1.88). Risk factors include AZTA's earnings volatility and higher beta, against XRAY's negative EPS (TTM) and elevated enterprise value. Market sentiment tilts toward AZTA for upside potential per targets.
Tickeron AI Verdict
Tickeron’s AI currently leans toward AZTA, citing superior recent trend consistency with 44% YTD gains and stronger positioning in high-growth life sciences amid biotech catalysts. While XRAY offers value and stability, AZTA's relative momentum and analyst upside (nearly 90% potential) suggest higher probabilistic edge in prevailing conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZTA is a Hold and XRAY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZTA’s FA Score shows that 0 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).
- AZTA’s FA Score: 0 green, 5 red.
- XRAY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZTA’s TA Score shows that 5 TA indicator(s) are bullish while XRAY’s TA Score has 4 bullish TA indicator(s).
- AZTA’s TA Score: 5 bullish, 5 bearish.
- XRAY’s TA Score: 4 bullish, 4 bearish.
Price Growth
AZTA (@Pharmaceuticals: Other) experienced а -28.73% price change this week, while XRAY (@Pharmaceuticals: Other) price change was -3.25% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.56%. For the same industry, the average monthly price growth was +2.89%, and the average quarterly price growth was +23.09%.
Reported Earning Dates
AZTA is expected to report earnings on Aug 11, 2026.
XRAY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.56% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| AZTA | XRAY | AZTA / XRAY | |
| Capitalization | 808M | 2.2B | 37% |
| EBITDA | 36.6M | -127M | -29% |
| Gain YTD | -47.264 | -3.762 | 1,256% |
| P/E Ratio | 42.43 | N/A | - |
| Revenue | 596M | 3.68B | 16% |
| Total Cash | 381M | 190M | 201% |
| Total Debt | 55.7M | 2.33B | 2% |
AZTA | XRAY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 67 Overvalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 97 | |
PRICE GROWTH RATING 1..100 | 89 | 64 | |
P/E GROWTH RATING 1..100 | 85 | 82 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRAY's Valuation (2) in the Medical Specialties industry is somewhat better than the same rating for AZTA (67) in the Electronic Production Equipment industry. This means that XRAY’s stock grew somewhat faster than AZTA’s over the last 12 months.
XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as AZTA (100) in the Electronic Production Equipment industry. This means that XRAY’s stock grew similarly to AZTA’s over the last 12 months.
AZTA's SMR Rating (93) in the Electronic Production Equipment industry is in the same range as XRAY (97) in the Medical Specialties industry. This means that AZTA’s stock grew similarly to XRAY’s over the last 12 months.
XRAY's Price Growth Rating (64) in the Medical Specialties industry is in the same range as AZTA (89) in the Electronic Production Equipment industry. This means that XRAY’s stock grew similarly to AZTA’s over the last 12 months.
XRAY's P/E Growth Rating (82) in the Medical Specialties industry is in the same range as AZTA (85) in the Electronic Production Equipment industry. This means that XRAY’s stock grew similarly to AZTA’s over the last 12 months.
| AZTA | XRAY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 69% | N/A |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 75% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 74% |
| Advances ODDS (%) | 5 days ago 70% | 12 days ago 54% |
| Declines ODDS (%) | 14 days ago 82% | 6 days ago 73% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 56% |
| Aroon ODDS (%) | 2 days ago 80% | 2 days ago 62% |
Advertisement
AZTA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZTA has been loosely correlated with XRAY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if AZTA jumps, then XRAY could also see price increases.
| Ticker / NAME | Correlation To AZTA | 1D Price Change % | ||
|---|---|---|---|---|
| AZTA | 100% | -2.28% | ||
| XRAY - AZTA | 63% Loosely correlated | +0.82% | ||
| IQV - AZTA | 60% Loosely correlated | +0.87% | ||
| RVTY - AZTA | 59% Loosely correlated | +0.35% | ||
| A - AZTA | 59% Loosely correlated | +1.29% | ||
| MTD - AZTA | 59% Loosely correlated | -0.56% | ||
More | ||||
XRAY and
Correlation & Price change
A.I.dvisor indicates that over the last year, XRAY has been closely correlated with NVST. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if XRAY jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To XRAY | 1D Price Change % | ||
|---|---|---|---|---|
| XRAY | 100% | +0.82% | ||
| NVST - XRAY | 67% Closely correlated | +0.33% | ||
| BLFS - XRAY | 50% Loosely correlated | -2.35% | ||
| QDEL - XRAY | 50% Loosely correlated | +11.55% | ||
| ALGN - XRAY | 50% Loosely correlated | +0.72% | ||
| KIDS - XRAY | 48% Loosely correlated | +3.26% | ||
More | ||||